Biotech Values

[DewDiligence]

Copaxone Continues to Clean Tysabri’s Clock in US Market

There’s been a considerable amount of spin by a certain poster on
this board about Tysabri’s “resurgence.” Below are the Tysabri and
Copaxone numbers for US sales as well as the year-over-year and
quarter-over-quarter growth rates. One of these drugs is indeed
surging, but it isn’t Tysabri.

 
        -------TYSABRI-------    ------COPAXONE-------  
        US $M  Y-o-Y   Q-o-Q     US $M  Y-o-Y   Q-o-Q 
        Sales  Change  Change    Sales  Change  Change  
  3Q09   131    +7%     +5%       540   +53%    +23% 
  2Q09   125                      438 
  1Q09   116                      430 
  4Q08   115                      384 
  3Q08   122                      352